MedPage Today on MSN
Case Study: Where Did These Itchy, Burning Lesions Come From?
Patient also had seemingly unexplained concomitant mild anemia, leukocytosis, and eosinoph ...
Allegheny Health Network (AHN) welcomed more than 8,700 babies into the world in 2025, a record-breaking year for the western-Pennsylvania based health system. Of all the little bundles of joy, the ...
First in a three-part series. As a laser burned away the hair on her leg, Samar El Hussein felt searing pain. An electrologist at The Refinery Medspa in West Melbourne assured her the work was ...
News-Medical.Net on MSN
New guidelines outline comprehensive care for acute pulmonary embolism
Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical. Comprehensive ...
The first clinical practice guideline on acute pulmonary embolism (PE) from the American Heart Association and the American ...
DALLAS and WASHINGTON - Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is ...
The Hearty Soul on MSN
Warning over Zoloft (sertraline) as symptoms of potentially lethal side effect explained
Sertraline is one of the most prescribed antidepressants, and many people take it for years. Most side effects stay mild, especially during the first weeks. However, a small group of reactions ...
Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as ...
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned ...
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related ...
Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...
Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Monday that the European Commission has approved subcutaneous Rybrevant (amivantamab) for every-three-week and every-four-week dosing schedules ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results